newsfilter
← Latest News
GlobeNewswire·

Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

  • Esperion, a company wholly-owned by ARCHIMED, has entered a settlement agreement with Aurobindo Pharma Limited to resolve patent litigation regarding generic versions of NEXLETOL & NEXLIZET.
  • Under the agreement, Aurobindo is prohibited from marketing generic versions of NEXLETOL & NEXLIZET in the United States prior to April 19, 2040, subject to limited customary circumstances.
  • Patent litigation against remaining defendants MSN Pharmaceuticals Inc. & Sandoz Inc. remains ongoing with no assurance that generic versions will be blocked prior to April 19, 2040.
  • Esperion is a commercial-stage biopharmaceutical company specializing in ACLY biology & currently markets two non-statin therapies for LDL-C management & cardiovascular risk.
  • ARCHIMED is a leading healthcare investment firm managing €9 billion across global offices, serving as the strategic & financial partner for Esperion.
Company
Esperion Therapeutics, Inc.
Keywords
Nasdaq:ESPR, Esperion Therapeutics, Inc.